Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
PHILADELPHIA and OXFORD, U.K., May 02, 2017 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will be presenting at the Deutsche Bank 42nd Annual Health Care Conference on Thursday, May 4, 2017 at 1:10 PM EDT (6:10 PM BST). The conference is being held at the InterContinental Boston Hotel in Boston, MA. Adaptimmune’s presentation will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conference.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 13, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts Juli P. Miller, Ph.D. T: (215) 825-9310 E: [email protected] Media Relations Margaret Henry T: +44 (0)1235 430036 Mobile: +44 (0)7710 304249 E: [email protected]
